B cell biomarkers of rituximab responses in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 3038-3047

  Vital, Edward M ^a   Dass, Shouvik ^a   Buch, Maya H ^a   Henshaw, Karen ^a   Pease, Colin T ^a   Martin, Michael F ^a   Ponchel, Frederique ^a   Rawstron, Andrew C ^b,c   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; STEROID;

ARTICLE; B LYMPHOCYTE; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FLOW CYTOMETRY; FOLLOW UP; HIGHLY SENSITIVE FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MEMORY CELL; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; METHYLPREDNISOLONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80053542023     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30466     Document Type: Article

References (22)

1. Cervera R, Khamashta MA, Hughes GR,. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009; 18: 869-74.
2. Rahman A, Isenberg DA,. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39. (Pubitemid 351397092)
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. (Pubitemid 44497758)
4. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
5. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al, for the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
6. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA,. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-76.
7. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1724-31.
8. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-7. (Pubitemid 46929903)
9. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA,. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66: 1259-62. (Pubitemid 47309748)
10. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9. (Pubitemid 39062719)
11. Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR Study [abstract]. Arthritis Rheum 2009; 60 Suppl: S429.
12. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
13. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-56. (Pubitemid 47502752)
14. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P,. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2993-9.
15. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-9. (Pubitemid 46224116)
16. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-58. (Pubitemid 23223653)
17. Vital EM, Dass S, Buch MH, Pease CT, Martin MF, Rawstron AC, et al. Rituximab in cutaneous lupus: responsiveness depends on pattern of skin involvement [abstract]. Arthritis Rheum 2009; 60 Suppl: S101.
18. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
19. Dass S, Vital EM, Buch MH, Rawstron AC, Bingham SJ, Ponchel F, et al. Effect of concomitant DMARD on B cell depletion with rituximab in rheumatoid arthritis [abstract]. Ann Rheum Dis 2009; 68 Suppl III: iii579.
20. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011-6. (Pubitemid 351956665)
21. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA,. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-5. (Pubitemid 41742472)
22. Ramos-Casals M, Diaz-Lagares C, Khamashta MA,. Rituximab and lupus: good in real life, bad in controlled trials: comment on the article by Lu et al [letter]. Arthritis Rheum 2009; 61: 1281-2.